BioSpace News Archive

Drug Development

Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R2) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018

Celgene Corporation announced additional results from RELEVANCE, a phase III, randomized, open-label, international clinical study conducted in partnership with the Lymphoma Academic Research Organisation (LYSARC), were presented at the 54th Annual American Society of Clinical Oncology Scientific Sessions (ASCO).

June 3, 2018
·
20 min read
Drug Development

BerGenBio Provides Interim Update on Phase II Clinical Programme With Selective Oral AXL Inhibitor Bemcentinib

BerGenBio ASA announces that interim data from its Phase II clinical development programme with bemcentinib, a selective AXL inhibitor, was presented at a reception hosted yesterday by the company in Chicago, IL, USA.

June 3, 2018
·
8 min read
Pharm Country

Children’s Hospital of Philadelphia Celebrates 22nd Annual Fetal Surgery Family Reunion

More than 2,000 people, including patients and families from over 22 states, found an important reason to return to Children’s Hospital of Philadelphia (CHOP) - the Annual Fetal Surgery Family Reunion.

June 3, 2018
·
3 min read
Job Trends

Susan G. Komen Statement on TAILORx Study Citing Chemotherapy Not Needed for Some Breast Cancer Patients

Susan G. Komen® issued the following statement today regarding a new study partially funded by the organization – called Trial Assigning Individualized Options for Treatment, or TAILORx.

June 3, 2018
·
3 min read
Drug Development

Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy

Jazz Pharmaceuticals plc announced that Xyrem® (sodium oxybate) oral solution, CIII, demonstrated long-term efficacy for up to one year in reducing cataplexy and excessive daytime sleepiness (EDS) in the global Phase 2/3 EXPRESS study of pediatric patients seven to 17 years of age with narcolepsy.

June 3, 2018
·
8 min read
Drug Development

Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc announced that its investigational treatment solriamfetol demonstrated long-term maintenance of efficacy and a tolerable safety profile in the open-label Phase 3 TONES 5 study of excessive sleepiness (ES) in patients with narcolepsy or obstructive sleep apnea (OSA).

June 3, 2018
·
8 min read
Drug Development

Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types

Eisai Inc. and Merck announced results from presentations of new data and analyses of LENVIMA® (lenvatinib).

June 3, 2018
·
44 min read
Global Cerebral and Tissue Oximetry Devices Market| Key Insights and Forecasts| Technavio

Market research firm Technavio has announced the release of their latest report on the global cerebral and tissue oximetry devices market.

June 3, 2018
·
4 min read
Global Fractional Flow Reserve Market| New Market Research Report| Technavio

Market research firm Technavio has announced the release of their latest report on the global fractional flow reserve market.

June 3, 2018
·
3 min read
Genetown

Sensera’s MEMS Mimic Human Organs Through Bioengineering

Sensera Inc. is adapting its technology for new applications in bioengineering.

June 3, 2018
·
2 min read